{"id":"pegylated-formula-interferon-alpha-2b","safety":{"commonSideEffects":["Flu-like symptoms","Fatigue","Neutropenia","Depression","Injection site reactions"],"contraindications":["Autoimmune hepatitis","Hepatic decompensation","Severe psychiatric disorders"]},"_chembl":null,"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"Type I interferon receptor (IFNAR)","explanation":"Pegylated interferon-alpha 2b binds to type I interferon receptors on cell surfaces, activating JAK-STAT signaling pathways. This triggers antiviral, antiproliferative, and immunomodulatory effects including enhanced natural killer cell activity and increased MHC class I expression.","oneSentence":"Stimulates immune responses and inhibits cell proliferation through interferon receptor signaling pathways."},"_scrapedAt":"2026-03-28T00:47:59.313Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779122732,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"rituximab","brand":"Rituxan","company":"Genentech/Roche","rationale":"Standard maintenance therapy for mantle cell lymphoma"},{"name":"bortezomib","brand":"Velcade","company":"Takeda","rationale":"Approved for relapsed/refractory mantle cell lymphoma"},{"name":"ibrutinib","brand":"Imbruvica","company":"Pharmacyclics/Janssen","rationale":"BTK inhibitor approved for mantle cell lymphoma"}],"description":"Pegylated interferon-alpha 2b is a modified form of interferon-alpha 2b with polyethylene glycol (PEG) attached to extend its half-life. It has been investigated by the European Mantle Cell Lymphoma Network in phase 3 trials for hematologic malignancies, building on interferon's immunomodulatory and antiproliferative properties.","indications":{"approved":[{"status":"investigational","condition":"Mantle cell lymphoma","patientPopulation":"Adult, maintenance therapy"}]},"trialDetails":[{"nctId":"NCT00209209","phase":"PHASE3","title":"Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL","status":"UNKNOWN","sponsor":"European Mantle Cell Lymphoma Network","startDate":"2004-01-14","conditions":"Lymphoma, Mantle-Cell","enrollment":570}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"pegylated formula Interferon-alpha 2b","genericName":"pegylated formula Interferon-alpha 2b","companyName":"European Mantle Cell Lymphoma Network","companyId":"european-mantle-cell-lymphoma-network","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}